Our study provides the first evidence that Cav-1 acts as a modulator in activating the WNT/β-catenin pathway in GC cells, which would facilitate the development of new treatments for cisplatin resistance of GC patients by targeting the Met expression. This evidence concerns the gene CAV1 and gastric cancer.